Chembio Diagnostics Profit Margin

Chembio Diagnostics (CEMI) currently reports a profit margin of -51.56% as of December 2022. That compares with -91.81% in the prior-year period — up 43.8% year over year. That is below the Healthcare sector average of 13.76%. Use the charts on this page to explore Chembio Diagnostics's profit margin history and peer comparisons.

Chembio Diagnostics's profit margin increased from -91.81% to -51.56% — a 43.8% year-over-year increase (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Chembio Diagnostics's profit margin of -51.56% is lower than the Healthcare sector average of 13.76%. That is roughly 474.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Chembio Diagnostics's current -51.56% should be judged against Healthcare norms (sector average: 13.76%) and against CEMI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -51.56%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.76%. From there, open related valuation or income-statement pages for Chembio Diagnostics, and consider following CEMI for alerts when major investors trade the stock.